11:36:05 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-27 Bokslutskommuniké 2024
2024-11-28 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-16 Kvartalsrapport 2024-Q1
2024-05-13 Ordinarie utdelning DEAR 0.00 SEK
2024-05-08 Årsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2024-01-31 Extra Bolagsstämma 2024
2023-11-30 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-04 Kvartalsrapport 2023-Q1
2023-04-13 Ordinarie utdelning DEAR 0.00 SEK
2023-04-12 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Kvartalsrapport 2022-Q1
2022-04-08 Ordinarie utdelning DEAR 0.00 SEK
2022-04-07 Årsstämma 2022

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Duearity är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling och produktion av tekniska lösningar för behandling och lindring av tinnitus. Produktportföljen inkluderar exempelvis bolagets egenutvecklade produkter Tinearity och Duearity. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten bedrivs inom Sverige.
2023-07-27 10:22:00

Duearity AB has today entered into an agreement with a distributor in Great Britain. The goal is to sell more than a couple of thousand Tinearity G1 start kits in the UK per year after full launch and then increase the sales. The agreement is Duearity's second distributor agreement, and the company is expected to enter into more distributor agreements and agreements with clinics in Europe and the US during 2023.

The distributor has carried out a solid analysis of Tinearity G1's conditions in Great Britain, through contacts with expertise in the field of tinnitus. The distributor agreement is implemented immediately and the marketing and sales in the UK start in August this year. According to the distributor, a reasonable goal is to sell more than a couple of thousand Tinearity G1 starter kits per year after full launch and then increase sales. Following approval by the NHS in Great Britain, the aim is to sell more than 5,000 Tinearity G1 starter kits per year.

The distributor intends to initiate a pilot study which will be used for the purpose of Tinearity G1 being approved by the NHS, the British subsidy system. Tinearity G1 is expected to be approved by the NHS in 2024.

- Our agreement with the distributor in the UK is yet another proof that Duearity offers a product that fulfills an important function in the treatment of people who suffer or are bothered by tinnitus. The UK has a well-developed care for tinnitus patients and the market will be important for the company as we now enter a growth phase, says Fredrik Westman, CEO of Duearity AB.

The distributor company, Prime Health Distribution Ltd, which is owned by Marta Neto and Phil Bradshaw, has been active in the ear and hearing field for 30 years and has a very large network of contacts among clinics, doctors, audiologists and the British patient organization British Tinnitus. The distributor company will focus solely on the marketing and sales of Tinearity G1.

The agreement is Duearity's second distributor agreement, and we will enter into more agreements in Europe and USA during 2023.